USRE38102EExpiredUtility

Use of a pyridazinone derivative

71
Assignee: ORION CORPPriority: Jun 19, 1998Filed: May 17, 2001Granted: Apr 29, 2003
Est. expiryJun 19, 2018(expired)· nominal 20-yr term from priority
A61P 9/06A61P 9/04A61P 43/00A61K 31/50A61P 9/00
71
PatentIndex Score
5
Cited by
22
References
8
Claims

Abstract

A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.

Claims

exact text as granted — not AI-modified
We claim:  
     
       1. A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment. 
     
     
       2. The method according to  claim 1 , wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day. 
     
     
       3. The method according to  claim 2 , wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day. 
     
     
       4. A method of increasing calcium sensitivity of troponin, which method comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahyro-4-methyl-6-oxo-3pyridazinyl)phenyl]acetamide to a mammal. 
     
     
       5. The method acording to  claim 4 , wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day. 
     
     
       6. The method according to  claim 5 , wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day. 
     
     
       7. A method of increasing calcium sensitivity of contractile proteins of cardiac muscle in a mammal, which method comprises administering an effective amount of ( R )- N -[   4   -(   1 , 4 , 5 , 6   - tetrahydro -   4   - methyl -   6   - oxo -   3   - pyridazinyl ) phenyl]acetamide to the mammal.    
     
     
       8. A method for reducing the need for neurohumoral activation in a patient, which comprises administering to the patient an effective amount of ( R )- N -[   4   -(   1 , 4 , 5 , 6   - tetrahydro -   4   - methyl -   6   - oxo -   3   - pyridazinyl ) phenyl]acetamide.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.